Ramucirumab

Hemorrhage, Gastrintestinal Perforation , and Impaired Wound Healing

• Hemorrhage: CYRAMZA increased the risk of hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events. Permanently discontinue CYRAMZA in patients who experience severe bleeding [see Dosage and Administration (2.3), Warnings and Precautions (5.1)].
• Gastrointestinal Perforation: CYRAMZA can increase the risk of gastrointestinal perforation, a potentially fatal event. Permanently discontinue CYRAMZA in patients who experience a gastrointestinal perforation [see Dosage and Administration (2.3), Warnings and Precautions (5.5)].
• Impaired Wound Healing: Impaired wound healing can occur with antibodies inhibiting the VEGF pathway. Discontinue CYRAMZA therapy in patients with impaired wound healing. Withhold CYRAMZA prior to surgery and discontinue CYRAMZA if a patient develops wound healing complications [see Dosage and Administration (2.3), Warnings and Precautions (5.6)].

Patient Counseling Information

• CYRAMZA

Package Inserts

Ramucirumab